Press Releases

BOSTON , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the pricing of its initial public offering of 5,666,667 shares
February 27, 2019 —Janus Henderson Investors joins Investor Group   BOSTON, MA. and STOCKHOLM, SWEDEN, February 27, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced that funds managed
December 2, 2018 — 95% ORR (by IWG) in 20 evaluable patients 70% complete remission (CR) rate in 20 evaluable patients No dose-limiting toxicities to date       BOSTON, MA. and STOCKHOLM, SWEDEN, December 2, 2018 – Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase